Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
12 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 38 | Sep 25, 2026 | clinicaltrials |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | recruiting | Phase 3 | 1,314 | Merck Sharp & Dohme LLCINDUSTRY |
| 39 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | recruiting | Phase 3 | 3,500 | Merck Sharp & Dohme LLCINDUSTRY | 51 | Sep 17, 2026 | clinicaltrials |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy | recruiting | Phase 3 | 670 | Boehringer IngelheimINDUSTRY | 42 | Sep 15, 2026 | clinicaltrials |
| NCT06774131 | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | recruiting | Phase 3 | 70 | UroGen Pharma Ltd.INDUSTRY | 9 | Sep 3, 2026 | clinicaltrials |
| NCT07140172 | Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery(OPBC-10/ NOAX) | recruiting | N/A | 1,060 | University Hospital, Basel, SwitzerlandOTHER | 11 | Aug 7, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT07439458 | Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity(TCReX) | recruiting | N/A | 40 | Riga Stradins UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02047994 | Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality(GISTAR) | recruiting | Phase 4 | 30,000 | International Agency for Research on CancerOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06275204 | H. Pylori Screen-and-treat Study in a Population of Young Adults | recruiting | — | 6,800 | University of LatviaOTHER | 6 | Mar 5, 2024 | clinicaltrials |
| NCT04022109 | Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach(VOGAS) | recruiting | — | 5,000 | University of LatviaOTHER | 5 | Jul 26, 2021 | clinicaltrials |
| NCT03250091 | Surveillance of Patients With Precancerous Lesions of the Stomach | recruiting | — | 2,000 | University of LatviaOTHER | 1 | Aug 21, 2018 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials